Assessment report for Lucentis (ranibizumab) 13 October 2016, EMA/757247/2016.
"In line with the Guideline on the environmental risk assessment of medicinal products for human use (CHMP/SWP/4447/00 corr 2), since ranibizumab is a protein and unlikely to result in a significant risk to the environment, there is no need for ERA studies."
Fass environmental information for Lucentis from Novartis (downloaded 2019-08-21).
The use of amino acids, proteins and peptides is not considered to have any environmental impact.
According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00) vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.
Author: Health and Medical Care Administration, Region Stockholm